OS Therapies (NYSEAMERICAN:OSTX – Get Free Report) issued its earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.10), Zacks reports.
OS Therapies Price Performance
Shares of OS Therapies stock traded up $0.13 during trading on Wednesday, hitting $0.88. The company’s stock had a trading volume of 253,272 shares, compared to its average volume of 660,280. The stock has a 50-day moving average price of $1.39 and a two-hundred day moving average price of $1.53. OS Therapies has a 52 week low of $0.58 and a 52 week high of $2.25. The stock has a market cap of $40.55 million, a price-to-earnings ratio of -0.79 and a beta of -0.47.
OS Therapies Company Profile
OS Therapies is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare bone cancer, and potentially other cancers. Its work centers on therapies intended to address the significant risk of recurrence and spread associated with the disease. The company’s lead candidate, OST-HER2, is an investigational immunotherapy designed to stimulate an immune response against HER2-expressing cancer cells. OS Therapies has studied it for osteosarcoma, including disease that has spread to the lungs.
Further Reading
- Five stocks we like better than OS Therapies
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
